DK173085B1 - Fremgangsmåde til bakteriel polypeptidudtrykkelse og plasmidisk udtrykkelsesmedium til fremstilling af et heterologt polype - Google Patents

Fremgangsmåde til bakteriel polypeptidudtrykkelse og plasmidisk udtrykkelsesmedium til fremstilling af et heterologt polype Download PDF

Info

Publication number: DK173085B1
Authority: DK; Denmark
Prior art keywords: polypeptide; trp; plasmid; heterologous; expression
Prior art date: 1980-03-24

Application number

DK198101299A

Other languages

Danish (da)

English (en)

Other versions

DK129981A (da

Inventor

Dennis G Kleid

Daniel G Yansura

Herbert L Heyneker

Giuseppe F Miozzari

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-03-24

Filing date

1981-03-23

Publication date

1999-12-27

1981-03-23 Application filed by Genentech Inc filed Critical Genentech Inc

1981-09-25 Publication of DK129981A publication Critical patent/DK129981A/da

1999-12-27 Application granted granted Critical

1999-12-27 Publication of DK173085B1 publication Critical patent/DK173085B1/da

Links

239000013612 plasmid Substances 0.000 title claims description 116
229920001184 polypeptide Polymers 0.000 title claims description 115
108090000765 processed proteins & peptides Proteins 0.000 title claims description 113
102000004196 processed proteins & peptides Human genes 0.000 title claims description 112
230000014509 gene expression Effects 0.000 title claims description 56
230000001580 bacterial effect Effects 0.000 title claims description 13
208000037062 Polyps Diseases 0.000 title 1
108090000623 proteins and genes Proteins 0.000 claims description 150
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 69
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 69
102000004169 proteins and genes Human genes 0.000 claims description 61
108020004414 DNA Proteins 0.000 claims description 47
238000000034 method Methods 0.000 claims description 38
241000588724 Escherichia coli Species 0.000 claims description 32
150000001413 amino acids Chemical group 0.000 claims description 27
239000002131 composite material Substances 0.000 claims description 25
239000002773 nucleotide Substances 0.000 claims description 22
125000003729 nucleotide group Chemical group 0.000 claims description 22
239000013598 vector Substances 0.000 claims description 21
108010000521 Human Growth Hormone Proteins 0.000 claims description 18
108010056088 Somatostatin Proteins 0.000 claims description 18
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 18
102000002265 Human Growth Hormone Human genes 0.000 claims description 17
239000000854 Human Growth Hormone Substances 0.000 claims description 17
102000005157 Somatostatin Human genes 0.000 claims description 17
229960000553 somatostatin Drugs 0.000 claims description 17
241000894006 Bacteria Species 0.000 claims description 15
239000000203 mixture Substances 0.000 claims description 15
238000013519 translation Methods 0.000 claims description 14
102000053602 DNA Human genes 0.000 claims description 10
101000976075 Homo sapiens Insulin Proteins 0.000 claims description 8
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 8
230000008569 process Effects 0.000 claims description 8
108091033380 Coding strand Proteins 0.000 claims description 7
102000004190 Enzymes Human genes 0.000 claims description 7
108090000790 Enzymes Proteins 0.000 claims description 7
239000013604 expression vector Substances 0.000 claims description 6
239000000463 material Substances 0.000 claims description 6
WTFXTQVDAKGDEY-UHFFFAOYSA-N (-)-chorismic acid Natural products OC1C=CC(C(O)=O)=CC1OC(=C)C(O)=O WTFXTQVDAKGDEY-UHFFFAOYSA-N 0.000 claims description 4
LXCUAFVVTHZALS-UHFFFAOYSA-N 3-(3-methoxyphenyl)piperidine Chemical compound COC1=CC=CC(C2CNCCC2)=C1 LXCUAFVVTHZALS-UHFFFAOYSA-N 0.000 claims description 4
WTFXTQVDAKGDEY-HTQZYQBOSA-N Chorismic acid Natural products O[C@@H]1C=CC(C(O)=O)=C[C@H]1OC(=C)C(O)=O WTFXTQVDAKGDEY-HTQZYQBOSA-N 0.000 claims description 4
108010076181 Proinsulin Proteins 0.000 claims description 4
108010078233 Thymalfasin Proteins 0.000 claims description 3
102400000800 Thymosin alpha-1 Human genes 0.000 claims description 3
230000000975 bioactive effect Effects 0.000 claims description 3
230000001851 biosynthetic effect Effects 0.000 claims description 3
238000010790 dilution Methods 0.000 claims description 3
239000012895 dilution Substances 0.000 claims description 3
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims description 3
229960004231 thymalfasin Drugs 0.000 claims description 3
230000000994 depressogenic effect Effects 0.000 claims description 2
240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
239000000654 additive Substances 0.000 claims 1
230000000996 additive effect Effects 0.000 claims 1
238000000855 fermentation Methods 0.000 claims 1
230000004151 fermentation Effects 0.000 claims 1
235000015097 nutrients Nutrition 0.000 claims 1
125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 88
239000012634 fragment Substances 0.000 description 83
229960004799 tryptophan Drugs 0.000 description 65
235000018102 proteins Nutrition 0.000 description 57
210000004027 cell Anatomy 0.000 description 37
229930101283 tetracycline Natural products 0.000 description 34
239000004098 Tetracycline Substances 0.000 description 30
229960002180 tetracycline Drugs 0.000 description 30
235000019364 tetracycline Nutrition 0.000 description 30
150000003522 tetracyclines Chemical class 0.000 description 30
239000000047 product Substances 0.000 description 29
238000003776 cleavage reaction Methods 0.000 description 26
230000007017 scission Effects 0.000 description 26
239000002609 medium Substances 0.000 description 23
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 22
108020004705 Codon Proteins 0.000 description 19
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
230000015556 catabolic process Effects 0.000 description 18
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 17
229960000723 ampicillin Drugs 0.000 description 17
238000006731 degradation reaction Methods 0.000 description 17
108091008146 restriction endonucleases Proteins 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 11
108020004999 messenger RNA Proteins 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
108010046075 Thymosin Proteins 0.000 description 10
102000007501 Thymosin Human genes 0.000 description 10
230000037431 insertion Effects 0.000 description 10
238000003780 insertion Methods 0.000 description 10
239000000499 gel Substances 0.000 description 9
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 9
101150044170 trpE gene Proteins 0.000 description 9
101100122010 Methanocella arvoryzae (strain DSM 22066 / NBRC 105507 / MRE50) glmM gene Proteins 0.000 description 8
238000010276 construction Methods 0.000 description 8
238000005516 engineering process Methods 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
239000013615 primer Substances 0.000 description 8
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 7
239000000872 buffer Substances 0.000 description 7
238000000605 extraction Methods 0.000 description 7
239000011541 reaction mixture Substances 0.000 description 7
108020004511 Recombinant DNA Proteins 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 6
238000012869 ethanol precipitation Methods 0.000 description 6
239000013613 expression plasmid Substances 0.000 description 6
230000003287 optical effect Effects 0.000 description 6
230000009466 transformation Effects 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
102000003960 Ligases Human genes 0.000 description 5
108090000364 Ligases Proteins 0.000 description 5
101710163270 Nuclease Proteins 0.000 description 5
101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 5
238000012258 culturing Methods 0.000 description 5
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 5
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 4
241001646716 Escherichia coli K-12 Species 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
101150100816 trpD gene Proteins 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
102000012410 DNA Ligases Human genes 0.000 description 3
108010061982 DNA Ligases Proteins 0.000 description 3
102000004594 DNA Polymerase I Human genes 0.000 description 3
108010017826 DNA Polymerase I Proteins 0.000 description 3
238000012270 DNA recombination Methods 0.000 description 3
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
108091081024 Start codon Proteins 0.000 description 3
239000000853 adhesive Substances 0.000 description 3
230000001070 adhesive effect Effects 0.000 description 3
RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
238000010367 cloning Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000008103 glucose Substances 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
239000002243 precursor Substances 0.000 description 3
238000005204 segregation Methods 0.000 description 3
-1 2-10 times dilution) Chemical compound 0.000 description 2
OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
101100269389 Mus musculus Pgm3 gene Proteins 0.000 description 2
102000009661 Repressor Proteins Human genes 0.000 description 2
108020004682 Single-Stranded DNA Proteins 0.000 description 2
101100046504 Symbiobacterium thermophilum (strain T / IAM 14863) tnaA2 gene Proteins 0.000 description 2
239000008051 TBE buffer Substances 0.000 description 2
108050004197 Trp repressor Proteins 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
230000001036 exonucleolytic effect Effects 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000006151 minimal media Substances 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
210000003705 ribosome Anatomy 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
230000009452 underexpressoin Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
NQEQTYPJSIEPHW-MNOVXSKESA-N (1S,2R)-1-C-(indol-3-yl)glycerol 3-phosphate Chemical compound C1=CC=C2C([C@H](O)[C@@H](COP(O)(O)=O)O)=CNC2=C1 NQEQTYPJSIEPHW-MNOVXSKESA-N 0.000 description 1
UTWSLTKGFRKQTA-QHPFDFDXSA-N 2-[[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-phosphonoamino]benzoic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)OC1N(P(O)(O)=O)C1=CC=CC=C1C(O)=O UTWSLTKGFRKQTA-QHPFDFDXSA-N 0.000 description 1
SXOUIMVOMIGLHO-UHFFFAOYSA-N 3-(1h-indol-2-yl)prop-2-enoic acid Chemical compound C1=CC=C2NC(C=CC(=O)O)=CC2=C1 SXOUIMVOMIGLHO-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
102000008169 Co-Repressor Proteins Human genes 0.000 description 1
108010060434 Co-Repressor Proteins Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
101150097493 D gene Proteins 0.000 description 1
FNZLKVNUWIIPSJ-UHNVWZDZSA-N D-ribulose 5-phosphate Chemical compound OCC(=O)[C@H](O)[C@H](O)COP(O)(O)=O FNZLKVNUWIIPSJ-UHNVWZDZSA-N 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
230000007023 DNA restriction-modification system Effects 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
101150013191 E gene Proteins 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
241000588921 Enterobacteriaceae Species 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FNZLKVNUWIIPSJ-UHFFFAOYSA-N Rbl5P Natural products OCC(=O)C(O)C(O)COP(O)(O)=O FNZLKVNUWIIPSJ-UHFFFAOYSA-N 0.000 description 1
108010034634 Repressor Proteins Proteins 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
241000607715 Serratia marcescens Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
229930003451 Vitamin B1 Natural products 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000005550 amino acid supplement Nutrition 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000009585 enzyme analysis Methods 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
210000003746 feather Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
238000009776 industrial production Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000005304 joining Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000000379 polymerizing effect Effects 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000007320 rich medium Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
108010068698 spleen exonuclease Proteins 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000037351 starvation Effects 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960004989 tetracycline hydrochloride Drugs 0.000 description 1
229960003495 thiamine Drugs 0.000 description 1
DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
101150079930 trpGD gene Proteins 0.000 description 1
239000012137 tryptone Substances 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
235000010374 vitamin B1 Nutrition 0.000 description 1
239000011691 vitamin B1 Substances 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Crystallography & Structural Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

DK198101299A 1980-03-24 1981-03-23 Fremgangsmåde til bakteriel polypeptidudtrykkelse og plasmidisk udtrykkelsesmedium til fremstilling af et heterologt polype DK173085B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13329680A	1980-03-24	1980-03-24
US13329680		1980-03-24

Publications (2)

Publication Number	Publication Date
DK129981A DK129981A (da)	1981-09-25
DK173085B1 true DK173085B1 (da)	1999-12-27

Family

ID=22457906

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198101299A DK173085B1 (da)	1980-03-24	1981-03-23	Fremgangsmåde til bakteriel polypeptidudtrykkelse og plasmidisk udtrykkelsesmedium til fremstilling af et heterologt polype

Country Status (35)

Country	Link
US (2)	US5888808A (fi)
EP (3)	EP0154133B1 (fi)
JP (3)	JPH0724582B2 (fi)
KR (2)	KR830005351A (fi)
AR (1)	AR248050A1 (fi)
AT (3)	ATE27306T1 (fi)
AU (3)	AU542640B2 (fi)
BG (3)	BG46005A3 (fi)
BR (1)	BR8101712A (fi)
CA (2)	CA1198068A (fi)
CS (3)	CS238645B2 (fi)
DD (3)	DD203746A5 (fi)
DE (5)	DE3177179D1 (fi)
DK (1)	DK173085B1 (fi)
DZ (1)	DZ278A1 (fi)
ES (3)	ES500617A0 (fi)
FI (3)	FI810876L (fi)
FR (2)	FR2480781B1 (fi)
GB (1)	GB2073203B (fi)
GR (1)	GR74818B (fi)
HU (1)	HU195534B (fi)
IE (3)	IE51894B1 (fi)
IL (3)	IL71885A (fi)
IT (1)	IT1144324B (fi)
MX (1)	MX7689E (fi)
MY (1)	MY8500896A (fi)
NO (3)	NO810986L (fi)
NZ (3)	NZ196584A (fi)
OA (1)	OA06774A (fi)
PH (4)	PH17537A (fi)
PL (2)	PL162227B1 (fi)
PT (1)	PT72716B (fi)
YU (2)	YU45534B (fi)
ZA (1)	ZA811368B (fi)
ZW (1)	ZW5481A1 (fi)

Families Citing this family (362)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1202581A (en) *	1980-03-27	1986-04-01	Saran A. Narang	Adaptor molecules for dna and their application to synthesis of gene-derived products
NZ196706A (en)	1980-04-03	1988-01-08	Biogen Nv	Dna sequences, recombinant dna molecules and processes for producing fibroblast interferon-like polypeptides; pharmaceutical and veterinary compositions
US4874702A (en) *	1980-09-08	1989-10-17	Biogen, Inc.	Vectors and methods for making such vectors and for expressive cloned genes
DK489481A (da) *	1980-11-10	1982-05-11	Searle & Co	Plasmidvektor og frmgangsmaade til fremstilling deraf
US5525484A (en) *	1981-01-16	1996-06-11	Genome Therapeutics Corp.	Recombinant DNA means and method for producing rennin, prorenin and pre-prorennin
BR8205954A (pt) *	1981-10-14	1983-09-13	Unilever Nv	Sequencia de dna,plasmidio recombinante,cultura bacteriana e microorganismos
JPS58110600A (ja) *	1981-12-25	1983-07-01	Kyowa Hakko Kogyo Co Ltd	ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
JPS58141796A (ja) *	1982-02-18	1983-08-23	Kyowa Hakko Kogyo Co Ltd	ペプチドの製造法
ATE64618T1 (de) *	1982-03-15	1991-07-15	Schering Corp	Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
US4499188A (en) *	1982-05-05	1985-02-12	Cetus Corporation	Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US4863855A (en) *	1982-05-14	1989-09-05	The Research Foundation Of State University Of New York	Novel cloning vehicles for polypeptide expression in microbial hosts
DE3378638D1 (de) *	1982-10-25	1989-01-12	Monsanto Co	Reca promoter dependent polypeptide production
IE56509B1 (en) *	1982-11-04	1991-08-28	Univ California	Methods for oncogenic detection
DE3247922A1 (de) *	1982-12-24	1984-06-28	Boehringer Ingelheim International GmbH, 6507 Ingelheim	Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
DK161152C (da)	1983-03-03	1991-11-11	Genentech Inc	Polypeptid med egenskaber som human beta-nervevaekstfaktor og fremgangsmaade til fremstilling deraf, dna-isolat omfattende en sekvens som koder for polypeptidet, replicerbar udtrykkelsesvektor for dna-sekvensen, rekombinant vaertscelle transformeret med vektoren, farmaceutisk praeparat indeholdende polypeptidet og fremg. der omfatter anvendelsen af polypeptidet til fremst. af et farmaceutisk praeparat
US5169762A (en) *	1983-03-03	1992-12-08	Genentech, Inc.	Human nerve growth factor by recombinant technology
US4701416A (en) *	1983-12-09	1987-10-20	Cetus Corporation	Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV
US4935370A (en) *	1983-12-23	1990-06-19	Pfizer Inc.	Expression plasmids for improved production of heterologous protein in bacteria
DE3587730T2 (de) *	1984-02-08	1994-05-05	Cetus Oncology Corp	Kontrollsysteme für rekombinant-manipulationen.
US5028531A (en) *	1984-03-19	1991-07-02	Fujisawa Pharmaceutical Company, Ltd.	IGF-I fusion proteins; protection of IGF-I from degradation by host cell; and processes for the production thereof
GB8407044D0 (en) *	1984-03-19	1984-04-26	Fujisawa Pharmaceutical Co	Producing human insulin
US4894334A (en) *	1984-03-28	1990-01-16	Cetus Corporation	Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US4656132A (en)	1984-03-28	1987-04-07	Cetus Corporation	Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US5268278A (en) *	1984-03-30	1993-12-07	Istituto Farmacologico Serono S.P.A.	Genetic expression of somatostatin as hybrid polypeptide
US4789702A (en) *	1984-05-18	1988-12-06	Cetus Corporation	Feline leukemia virus vaccine
US5683688A (en) *	1984-05-31	1997-11-04	Genentech, Inc.	Unglycosylated recombinant human lymphotoxin polypeptides and compositions
DE3585176D1 (de) *	1984-06-22	1992-02-27	Hitachi Ltd	Verfahren zum kontrollieren der zuechtung von rekombinanten.
JPS619282A (ja) *	1984-06-22	1986-01-16	Hitachi Ltd	遺伝子組換え菌の培養方法
EP0178764A1 (en) *	1984-08-28	1986-04-23	Genex Corporation	Method of stabilizing a host microorganism/expression vector system for large scale production of proteins
US4738921A (en) *	1984-09-27	1988-04-19	Eli Lilly And Company	Derivative of the tryptophan operon for expression of fused gene products
NZ213759A (en) *	1984-10-19	1989-01-27	Genentech Inc	Lhrh-ctp protein conjugates influencing prolactin fsh and lh release
US5075224A (en) *	1984-10-19	1991-12-24	Genentech, Inc.	Prepro-LHRH C-terminal peptide DNA
FI90990C (fi) *	1984-12-18	1994-04-25	Boehringer Ingelheim Int	Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
EP0211047B1 (en)	1985-01-28	1994-02-02	Xoma Corporation	Arab promoters and method of producing polypeptides, includinn cecropins, by microbiological techniques
IT1234977B (it) *	1985-03-22	1992-06-09	Serono Ist Farm	Espressione in e. coli polipeptidi ibridi contenenti la sequenza del fattore di rilascio dell'ormone della crescita
DK171161B1 (da) *	1985-03-28	1996-07-08	Hoffmann La Roche	Fremgangsmåde til påvisning af forekomst eller fravær af mindst én specifik nukleinsyresekvens i en prøve eller til skelnen mellem to forskellige nukleinsyresekvenser i denne prøve
US4683202A (en) *	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4965188A (en) *	1986-08-22	1990-10-23	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
GB8509289D0 (en) *	1985-04-11	1985-05-15	Fujisawa Pharmaceutical Co	Production of somatostatin
DE3526995A1 (de) *	1985-07-27	1987-02-05	Hoechst Ag	Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
ES2000858A6 (es) *	1985-08-12	1988-03-16	Syntex Inc	Un metodo para producir un vector de expresion bacteriano para la expresion de proteinas de fusion
AU6104586A (en) *	1985-08-12	1987-02-19	Malcolm A. Martin	Aids protein using trple gene
JPH0775536B2 (ja) *	1986-03-26	1995-08-16	猛小林	遺伝子組み換え菌を用いた酵素生産装置
DE3642096A1 (de) *	1986-12-10	1988-06-16	Boehringer Ingelheim Int	Pferde-(gamma)-interferon
US6994988B1 (en)	1987-02-12	2006-02-07	Genetech, Inc.	Methods and deoxyribonucleic acid for the preparation of tissue factor protein
JPH01247098A (ja) *	1988-03-30	1989-10-02	Hitachi Ltd	ヒトの上皮細胞増殖因子の遺伝子工学的生産方法
DE68915841T2 (de) *	1988-03-30	1995-02-02	Hitachi Chemical Co Ltd	Verfahren zur Herstellung von Epidermal-Wachstumsfaktor durch genetische Transformation.
JPH01247099A (ja) *	1988-03-30	1989-10-02	Hitachi Ltd	ヒトの上皮細胞増殖因子の遺伝子工学的生産方法
JPH0227993A (ja) *	1988-07-15	1990-01-30	Nippon Shinyaku Co Ltd	ｈＥＧＦの製法
IL92937A0 (en)	1989-01-31	1990-09-17	Us Health	Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
JP4236698B2 (ja)	1990-11-26	2009-03-11	ジェネティックスインスティチュート，リミテッドライアビリティカンパニー	宿主細胞でのｐａｃｅの発現およびその使用法
DE69312493T2 (de)	1992-06-03	1998-01-15	Genentech Inc	Varianten des gewebeplasminogenaktivators mit verbesserter therapeutischer wirkung
GB9325182D0 (en) *	1993-12-08	1994-02-09	T Cell Sciences Inc	Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US6001604A (en) *	1993-12-29	1999-12-14	Bio-Technology General Corp.	Refolding of proinsulins without addition of reducing agents
US5629167A (en)	1994-04-19	1997-05-13	Biocine S.P.A.	Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US5708142A (en)	1994-05-27	1998-01-13	Genentech, Inc.	Tumor necrosis factor receptor-associated factors
US7091008B1 (en)	1994-07-01	2006-08-15	The Board Of Regents Of The University Of Oklahoma	Hyaluronan synthase genes and expression thereof in Bacillus hosts
US6455304B1 (en)	1994-07-01	2002-09-24	The Board Of Regents Of The University Of Oklahoma	Hyaluronate synthase gene and uses thereof
US6951743B2 (en)	1997-10-31	2005-10-04	University Of Oklahoma Board Of Regents	Hyaluronan synthase genes and expression thereof in bacillus hosts
US6113905A (en) *	1995-01-06	2000-09-05	The Regents Of The University Of California	Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US6077510A (en) *	1995-01-06	2000-06-20	Regents Of The University Of California	Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US6015660A (en) *	1995-01-06	2000-01-18	The Regents Of The University Of California	Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US5795966A (en)	1995-02-22	1998-08-18	Immunex Corp	Antagonists of interleukin-15
ATE503013T1 (de)	1995-06-29	2011-04-15	Immunex Corp	Cytokin welches apoptose induziert
US6020473A (en)	1995-08-25	2000-02-01	Genentech, Inc.	Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en)	1995-08-25	2006-02-28	Genentech, Inc.	Variants of vascular endothelial cell growth factor
US6030945A (en) *	1996-01-09	2000-02-29	Genentech, Inc.	Apo-2 ligand
US6998116B1 (en)	1996-01-09	2006-02-14	Genentech, Inc.	Apo-2 ligand
EP1500702A1 (en)	1996-04-01	2005-01-26	Genentech, Inc.	APO-2LI and APO-3 apoptosis polypeptides from the TNFR1 familiy
US6100071A (en)	1996-05-07	2000-08-08	Genentech, Inc.	Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5851984A (en) *	1996-08-16	1998-12-22	Genentech, Inc.	Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) *	1996-08-16	2000-12-12	Genentech, Inc.	Uses of Wnt polypeptides
US6462176B1 (en)	1996-09-23	2002-10-08	Genentech, Inc.	Apo-3 polypeptide
US5990281A (en) *	1996-09-30	1999-11-23	Genentech, Inc.	Vertebrate smoothened proteins
US6544523B1 (en)	1996-11-13	2003-04-08	Chiron Corporation	Mutant forms of Fas ligand and uses thereof
EP2371962A3 (en)	1996-12-23	2011-12-21	Immunex Corporation	Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
WO1999021998A1 (en)	1997-10-29	1999-05-06	Genentech, Inc.	Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
CA2286326C (en) *	1997-04-04	2007-06-26	Adam L. Cohen	Article, method, and apparatus for electrochemical fabrication
US6448035B1 (en)	1997-04-24	2002-09-10	Immunex Corporation	Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US6384203B1 (en)	1999-05-12	2002-05-07	Immunex Corporation	Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6342369B1 (en)	1997-05-15	2002-01-29	Genentech, Inc.	Apo-2-receptor
JP2001523977A (ja)	1997-06-05	2001-11-27	ザユニバーシティオブテキサスシステムボードオブリージェンツ	Ａｐａｆ−１、ｃｅｄ−４ヒト相同体、カスパーゼ−３の活性化因子
CA2293740A1 (en)	1997-06-18	1998-12-23	Genentech, Inc.	Apo-2dcr, a tnf-related receptor
US6342220B1 (en)	1997-08-25	2002-01-29	Genentech, Inc.	Agonist antibodies
ATE421527T1 (de)	1997-08-27	2009-02-15	Novartis Vaccines & Diagnostic	Molekular-mimetika von meningokokkus b epitopen
US6610838B1 (en)	1997-09-10	2003-08-26	Symbicom Aktiebolag	P13 antigens from Borrelia
DE69839401T2 (de)	1997-09-18	2009-05-07	Genentech Inc., San Francisco	Dcr3 polypeptid, ein tnfr homolog
IL135051A0 (en)	1997-10-10	2001-05-20	Genentech Inc	Apo-3 ligand polypeptide
DK1029046T3 (da)	1997-10-29	2009-02-02	Genentech Inc	WNT-1 inducerbare gener
CN101113436B (zh)	1997-10-31	2013-02-06	俄克拉何马大学董事会	透明质酸合酶基因及其应用
CN1322121C (zh)	1997-10-31	2007-06-20	俄克拉何马大学董事会	透明质酸合酶基因及其应用
CN1263854C (zh)	1997-11-06	2006-07-12	启龙股份公司	奈瑟球菌抗原
US7192589B2 (en)	1998-09-16	2007-03-20	Genentech, Inc.	Treatment of inflammatory disorders with STIgMA immunoadhesins
CA2309358A1 (en)	1997-11-21	1999-06-03	Genentech, Inc.	A-33 related antigens and their pharmacological uses
DE69941567D1 (de)	1998-01-14	2009-12-03	Novartis Vaccines & Diagnostic	Antigene aus neisseria meningitidis
JP2002508962A (ja)	1998-01-15	2002-03-26	ジェネンテク・インコーポレイテッド	Ａｐｏ−２リガンド
US6727079B1 (en)	1998-02-25	2004-04-27	The United States Of America As Represented By The Department Of Health And Human Services	cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
NZ525914A (en)	1998-03-10	2004-03-26	Genentech Inc	Novel polypeptides and nucleic acids encoding the same
DK2016951T3 (da)	1998-03-17	2012-09-24	Genentech Inc	VEGF- og BMP1-homologe polypeptider
US20060188966A1 (en)	1998-04-02	2006-08-24	Deangelis Paul L	Natural, chimeric and hybrid glycosaminoglycan polymers and methods of making and using same
US7223571B2 (en)	1998-04-02	2007-05-29	The Board Of Regents Of The Universtiy Of Oklahoma	Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US6987023B2 (en)	1998-04-02	2006-01-17	The Board Of Regents Of The University Of Oklahoma	DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use
GB9808932D0 (en)	1998-04-27	1998-06-24	Chiron Spa	Polyepitope carrier protein
EP2261340B1 (en)	1998-05-01	2017-03-08	GlaxoSmithKline Biologicals SA	Neisseria meningitidis antigens and compositions
EP3112468A1 (en)	1998-05-15	2017-01-04	Genentech, Inc.	Il-17 homologous polypeptides and therapeutic uses thereof
EP1865061A3 (en)	1998-05-15	2007-12-19	Genentech, Inc.	IL-17 homologous polypeptides and therapeutic uses thereof
PT1076703E (pt)	1998-05-15	2007-10-10	Genentech Inc	''utilizações terapêuticas de polipéptido homólogos de il-17''
US20020172678A1 (en)	2000-06-23	2002-11-21	Napoleone Ferrara	EG-VEGF nucleic acids and polypeptides and methods of use
PT1105485E (pt)	1998-08-21	2006-11-30	Immunex Corp	Dna e polipeptídeos de il-1 epsilon humana
HUP0104996A2 (hu)	1998-09-03	2002-04-29	Bristol-Myers Squibb Co.	Enzimes oxidatív dezaminálási eljárás
EP1953229A3 (en)	1998-10-15	2008-12-24	Novartis Vaccines and Diagnostics, Inc.	Metastatic breast and colon cancer regulated genes
US7094581B2 (en)	1998-10-26	2006-08-22	The Board Of Regents Of The University Of Oklahoma	Hyaluronan synthases and methods of making and using same
WO2001027150A2 (en)	1999-10-14	2001-04-19	Clontech Laboratories Inc.	Anthozoa derived chromo/fluoroproteins and methods for using the same
DK1141331T3 (da)	1998-12-16	2009-01-05	Novartis Vaccines & Diagnostic	Human cyclinafhængig kinase (hPNQALRE)
EP2075335A3 (en)	1998-12-22	2009-09-30	Genentech, Inc.	Methods and compositions for inhibiting neoplastic cell growth
EP1141299A2 (en)	1998-12-23	2001-10-10	Genentech, Inc.	Il-1 related polypeptides
NZ530640A (en)	1999-04-30	2006-06-30	Chiron S	Conserved neisserial antigens
GB9911683D0 (en)	1999-05-19	1999-07-21	Chiron Spa	Antigenic peptides
EP1978029A3 (en)	1999-06-15	2008-10-15	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids endoding the same
US7101989B1 (en)	1999-07-09	2006-09-05	University Of North Carolina At Chapel Hill	DsrA protein and polynucleotides encoding the same
GB9916529D0 (en)	1999-07-14	1999-09-15	Chiron Spa	Antigenic peptides
CN1279054C (zh)	1999-10-20	2006-10-11	杰南技术公司	I型细胞因子受体tccr
CA2863668A1 (en)	1999-10-29	2001-05-03	Novartis Vaccines And Diagnostics S.R.L.	Neisserial antigenic peptides
US7078382B1 (en)	1999-11-02	2006-07-18	Genentech, Inc.	Modulation of eNOS activity and therapeutic uses thereof
NZ518530A (en)	1999-11-10	2004-10-29	Univ Washington	Compositions and methods for modulation of plant cell division using the revoluta protein
EP1250426A2 (en)	1999-12-01	2002-10-23	Genentech Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding same
EP1239869B1 (en)	1999-12-20	2013-08-28	Immunex Corporation	Tweak receptor
DK1897944T3 (da)	1999-12-23	2011-10-24	Genentech Inc	IL-17 homologe polypeptider og terapeutisk anvendelse deraf
US6555335B1 (en)	1999-12-30	2003-04-29	Genencor International, Inc.	Xylanase from Trichoderma reesei , method for production thereof, and methods employing this enzyme
ES2311016T3 (es)	2000-01-10	2009-02-01	Novartis Vaccines And Diagnostics, Inc.	Genes expresados diferencialmente en cancer de mama.
DE60137829D1 (de)	2000-01-13	2009-04-16	Genentech Inc	Menschliche stra6 polypeptide
CN1416352B (zh)	2000-01-17	2011-05-25	启龙股份公司	含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
AU2001252958A1 (en)	2000-03-23	2001-10-03	Elan Pharmaceuticals, Inc.	Compounds and methods to treat alzheimer's disease
US6992081B2 (en)	2000-03-23	2006-01-31	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
EP2792747A1 (en)	2000-06-23	2014-10-22	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648048A1 (en)	2000-06-23	2002-01-03	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6846813B2 (en)	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
CA2410972A1 (en)	2000-06-30	2002-01-10	Elan Pharmaceuticals, Inc.	Compounds to treat alzheimer's disease
ATE412009T1 (de)	2000-08-24	2008-11-15	Genentech Inc	Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en)	2000-09-01	2008-09-17	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2277896A1 (en)	2000-10-27	2011-01-26	Novartis Vaccines and Diagnostics S.r.l.	Nucleic acids and proteins from streptococcus groups A & B
US6673580B2 (en)	2000-10-27	2004-01-06	Genentech, Inc.	Identification and modification of immunodominant epitopes in polypeptides
GB0107658D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Streptococcus pneumoniae
GB0107661D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Staphylococcus aureus
WO2002081639A2 (en)	2001-04-06	2002-10-17	Georgetown University	Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en)	2001-04-06	2002-10-21	Georgetown University	Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en)	2001-04-06	2002-10-21	Georgetown University	Gene scc-112 and diagnostic and therapeutic uses thereof
IL158380A0 (en)	2001-04-16	2004-05-12	Wyeth Corp	Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US20060270003A1 (en)	2003-07-08	2006-11-30	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
ATE522623T1 (de)	2001-06-20	2011-09-15	Genentech Inc	Zusammensetzungen und verfahren zur behandlung und diagnose von lungentumoren
US6867189B2 (en)	2001-07-26	2005-03-15	Genset S.A.	Use of adipsin/complement factor D in the treatment of metabolic related disorders
WO2003010194A2 (en)	2001-07-27	2003-02-06	Chiron Srl.	Meningococcus adhesins nada, app and orf 40
MY144532A (en)	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
CN1575338B (zh)	2001-08-29	2012-05-16	杰南技术公司	具有促细胞分裂活性的Bv8的核酸和多肽
EP2153843B1 (en)	2001-09-18	2012-08-15	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
EP2335724A1 (en)	2001-12-12	2011-06-22	Novartis Vaccines and Diagnostics S.r.l.	Immunisation against chlamydia trachomatis
EP1456223B1 (en)	2001-12-19	2009-08-12	The University Of Chicago	Rapidly maturing fluorescent proteins and methods for using the same
NZ533933A (en)	2002-01-02	2008-06-30	Genentech Inc	Compositions and methods for the diagnosis and treatment of glioma tumor
EP2388265A1 (en)	2002-02-22	2011-11-23	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
US7244565B2 (en)	2002-04-10	2007-07-17	Georgetown University	Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en)	2002-04-10	2006-11-21	Georgetown University	Gene SHINC-2 and diagnostic and therapeutic uses thereof
CA2481507A1 (en)	2002-04-16	2003-10-30	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
AU2003239865A1 (en)	2002-05-24	2003-12-12	Restoragen Inc.	Method for universal enzymatic production of bioactive peptides
WO2003099854A2 (en)	2002-05-24	2003-12-04	Nps Allelix Corp.	Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
EP2305710A3 (en)	2002-06-03	2013-05-29	Genentech, Inc.	Synthetic antibody phage libraries
US7700571B2 (en)	2002-06-05	2010-04-20	Genentech, Inc.	Compositions and methods for liver growth and liver protection
EP1553912A4 (en)	2002-06-07	2007-08-08	Genentech Inc	COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
AU2003247806B2 (en)	2002-07-08	2009-11-12	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
DE60335552D1 (de)	2002-09-11	2011-02-10	Genentech Inc	Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
JP2006521082A (ja)	2002-09-11	2006-09-21	ジェネンテック・インコーポレーテッド	免疫関連疾患の治療のための新規組成物と方法
WO2004024097A2 (en)	2002-09-16	2004-03-25	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
EP1585482A4 (en)	2002-09-25	2009-09-09	Genentech Inc	NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS
JP4571862B2 (ja)	2002-10-04	2010-10-27	フイルメニツヒソシエテアノニム	セスキテルペン合成及び使用方法
AU2003298607B9 (en)	2002-10-29	2011-08-04	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
EP2364716A3 (en)	2002-11-08	2012-01-11	Genentech, Inc.	Compositions and methods for the treatment of natural killer cell related diseases
EP1562982B1 (en)	2002-11-15	2010-05-05	Novartis Vaccines and Diagnostics S.r.l.	Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
JP2011516026A (ja)	2002-11-26	2011-05-26	ジェネンテック・インコーポレーテッド	免疫関連疾患の治療のための組成物と方法
CN102225194B (zh)	2003-03-12	2014-07-16	健泰科生物技术公司	Bv8和/或EG-VEGF促进造血的用途
ZA200507757B (en)	2003-04-04	2007-01-31	Genentech Inc	High concentration antibody and protein formulations
GB0308198D0 (en)	2003-04-09	2003-05-14	Chiron Srl	ADP-ribosylating bacterial toxin
JP4850698B2 (ja)	2003-04-25	2012-01-11	ノース・キャロライナ・ステイト・ユニヴァーシティ	細胞表面タンパク質相同体をコードするアシドフィルス菌核酸配列及びその使用
DE602004032144D1 (de)	2003-06-23	2011-05-19	Univ North Carolina State	Für fructooligosaccharid-nutzende verbindungen codierende nukleinsäuren aus lactobacillus acidophilus und verwendungen davon
US7442785B2 (en)	2003-07-24	2008-10-28	The University Of Kentucky Research Foundation	Sesquiterpene synthase gene and protein
WO2005019258A2 (en)	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
WO2005030039A2 (en)	2003-09-23	2005-04-07	University Of North Carolina At Chapel Hill	Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage
ES2379764T3 (es)	2003-10-14	2012-05-03	Baxter International Inc.	Polipéptido VKORC1 de reciclaje de la vitamina K-epóxido, una diana terapéutica de la curamina y sus derivados
SI2295073T1 (sl)	2003-11-17	2014-07-31	Genentech, Inc.	Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
WO2005067368A2 (en)	2003-11-21	2005-07-28	Nps Allelix Corp.	Production of glucagon like peptide 2 and analogs
CA2553035A1 (en)	2004-02-02	2005-08-18	Ambrx, Inc.	Modified human growth hormone polypeptides and their uses
US7459289B2 (en)	2004-03-08	2008-12-02	North Carolina State University	Lactobacillus acidophilus nucleic acid sequences encoding carbohydrate utilization-related proteins and uses therefor
JP4792390B2 (ja)	2004-03-29	2011-10-12	株式会社ガルファーマ	新規ガレクチン９改変体タンパク質及びその用途
WO2005100387A1 (en)	2004-04-07	2005-10-27	The University Of Chicago	Monomeric red fluorescent proteins
EP1771205B1 (en)	2004-06-18	2016-10-26	Ambrx, Inc.	Novel antigen-binding polypeptides and their uses
CA2583121A1 (en)	2004-10-21	2007-01-04	Wyeth	Immunogenic compositions of staphylococcus epidermidis polypeptide antigens
SG160437A1 (en)	2004-12-22	2010-04-29	Ambrx Inc	Modified human growth hormone
EP2290086A3 (en)	2004-12-22	2011-10-19	Genentech, Inc.	Methods for producing soluble multi-membrane-spanning proteins
MX2007007590A (es)	2004-12-22	2007-12-10	Ambrx Inc	Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos.
AU2005329450A1 (en)	2005-03-15	2006-09-28	University Of North Carolina At Chapel Hill	Methods and compositions for producing active Vitamin K-dependent proteins
DK1865940T3 (da)	2005-03-21	2013-03-04	Virobay Inc	Alfaketoamidforbindelser som cysteinproteasehæmmere
AU2006236629B2 (en)	2005-04-15	2012-04-19	North Carolina State University	Methods and compositions to modulate adhesion and stress tolerance in bacteria
DK1877435T4 (da)	2005-05-04	2021-03-29	Zealand Pharma As	Glucagon-lignende-peptid-2 (glp-2)-analoger
WO2006124667A2 (en)	2005-05-12	2006-11-23	Zymogenetics, Inc.	Compositions and methods for modulating immune responses
EP2186402A1 (en)	2005-06-06	2010-05-19	Genentech, Inc.	Knock-out animal models for novel genes and methods of use
EP1924136A4 (en)	2005-07-29	2009-05-13	Targeted Growth Inc	PROTECTION OF DOMINANT NEGATIVE MUTANT KRP PROTEINS ACTIVE INHIBITION OF CYCLINE / CDK COMPLEX BY WILD TYPE KRP
AU2006280321A1 (en)	2005-08-15	2007-02-22	Genentech, Inc.	Gene disruptions, compositions and methods relating thereto
EP1919931A4 (en)	2005-08-31	2010-01-20	Univ California	CELLULAR PEPTIDE SEQUENCE LIBRARIES (CLIPS) AND METHOD OF USE THEREOF
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
DE102005048898A1 (de)	2005-10-12	2007-04-19	Sanofi-Aventis Deutschland Gmbh	EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
IL286053B2 (en)	2005-10-18	2023-03-01	Nat Jewish Health	A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin
WO2007053732A2 (en)	2005-11-01	2007-05-10	Mayo Foundation For Medical Education And Research	Promoter polymorphisms of the blys gene and use in diagnostic methods
CA2626522A1 (en)	2005-11-16	2007-05-24	Ambrx, Inc.	Methods and compositions comprising non-natural amino acids
WO2007081608A2 (en)	2005-11-21	2007-07-19	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
US8026354B2 (en)	2005-11-23	2011-09-27	Institut Pasteur	Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
EP2336164A1 (en)	2005-12-22	2011-06-22	Genentech, Inc.	Recombinant production of heparin binding proteins
WO2007114979A2 (en)	2006-02-17	2007-10-11	Genentech, Inc.	Gene disruptons, compositions and methods relating thereto
WO2008036437A2 (en)	2006-04-19	2008-03-27	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
US8592149B2 (en)	2006-04-27	2013-11-26	Pikamab, Inc.	Methods and compositions for antibody therapy
PT2054431E (pt)	2006-06-09	2011-11-03	Novartis Ag	Confórmeros de adesinas bacterianas
EP2035572A4 (en)	2006-06-30	2010-01-06	Univ Michigan	PROCESS FOR THE PREPARATION OF FACTOR VIII PROTEINS BY RECOMBINATION PROCEDURES
DK2615108T3 (en)	2006-09-08	2017-01-30	Ambrx Inc	Modified human plasma polypeptide or fc scaffolds and their applications
US7985783B2 (en)	2006-09-21	2011-07-26	The Regents Of The University Of California	Aldehyde tags, uses thereof in site-specific protein modification
ES2870017T3 (es)	2006-11-02	2021-10-26	Biomolecular Holdings Llc	Métodos de producción de polipéptidos híbridos con partes móviles
ES2556380T3 (es)	2007-02-22	2016-01-15	Genentech, Inc.	Procedimientos para detectar una enfermedad inflamatoria del intestino
CA2682147C (en)	2007-03-30	2017-08-08	Ambrx, Inc.	Modified fgf-21 polypeptides and their uses
TWI412591B (zh)	2007-04-20	2013-10-21	Sigma Tau Rare Diseases S A	穩定的重組腺苷脫胺酶
US20100081187A1 (en)	2007-04-26	2010-04-01	Griffith Michael J	Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
BRPI0812691B8 (pt)	2007-07-16	2022-07-19	Genentech Inc	Anticorpos anti-cd79b, imunoconjugado, composições farmacêuticas, método de inibição do crescimento de uma célula que expressa cd79b, método de determinar a presença de cd79b e usos de um imunoconjugado
EP2641618A3 (en)	2007-07-16	2013-10-23	Genentech, Inc.	Humanized anti-CD79B antibodies and immunoconjugates and methods of use
US8293685B2 (en)	2007-07-26	2012-10-23	The Regents Of The University Of California	Methods for enhancing bacterial cell display of proteins and peptides
CN101361968B (zh)	2007-08-06	2011-08-03	健能隆医药技术（上海）有限公司	白介素-22在治疗脂肪肝中的应用
ES2908934T3 (es)	2007-10-04	2022-05-04	Zymogenetics Inc	ZB7H6 miembro de la familia B7 y composiciones y métodos relacionados
WO2009059305A2 (en)	2007-11-01	2009-05-07	The University Of Chicago	Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
US20090233991A1 (en)	2007-11-01	2009-09-17	Hee Cheol Cho	Generation of biological pacemaker activity
DK2217265T3 (en)	2007-11-20	2017-07-03	Ambrx Inc	Modified insulin polypeptides and their use
EP2586797A3 (en)	2007-11-27	2013-07-24	Medtronic, Inc.	Humanized anti-amyloid beta antibodies
US8003325B2 (en)	2007-11-30	2011-08-23	Mayo Foundation For Medical Education And Research	Polymorphisms of the BLyS gene and use in diagnostic methods
PL2247620T3 (pl)	2008-01-31	2017-08-31	Genentech, Inc.	Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
MX2010008632A (es)	2008-02-08	2010-08-30	Ambrx Inc	Leptina-polipeptidos modificados y sus usos.
BRPI0907843A2 (pt)	2008-02-21	2015-08-04	Novartis Ag	Polipeptídeos de fhbp menigocócicos
MX364200B (es)	2008-04-09	2019-04-16	Genentech Inc	Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
ES2820873T3 (es)	2008-05-16	2021-04-22	Taiga Biotechnologies Inc	Anticuerpos y su procesos de preparación
EA019968B1 (ru)	2008-07-23	2014-07-30	Амбркс, Инк.	Модифицированные бычьи полипептиды g-csf и их применение
DK3339321T3 (da)	2008-08-28	2021-06-21	Taiga Biotechnologies Inc	Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc
ES2660000T3 (es)	2008-09-26	2018-03-20	Ambrx, Inc.	Vacunas y microorganismos dependientes de la replicación de aminoácidos no naturales
CA2737026C (en)	2008-09-26	2019-12-24	Ambrx, Inc.	Modified animal erythropoietin polypeptides and their uses
US9702877B2 (en)	2008-10-31	2017-07-11	Quest Diagnostics Investments Incorporated	BCR-ABL variants
AU2009319772A1 (en)	2008-11-26	2010-06-03	Centocor Research & Development, Inc.	Compositions and methods for regulating collagen and smooth muscle actin expression by SERPINE2
US8673860B2 (en)	2009-02-03	2014-03-18	Amunix Operating Inc.	Extended recombinant polypeptides and compositions comprising same
MX2011010264A (es)	2009-04-01	2011-10-11	Genentech Inc	Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
EP2251025A1 (en)	2009-05-12	2010-11-17	Universitat Autònoma De Barcelona	Use of inclusion bodies as therapeutic agents
ITMI20090946A1 (it)	2009-05-28	2010-11-29	Novartis Ag	Espressione di proteine ricombinanti
JP5805634B2 (ja)	2009-06-08	2015-11-04	アムニクスオペレーティングインコーポレイテッド	成長ホルモンポリペプチド並びにその作成及び使用方法
NZ596778A (en)	2009-06-08	2013-11-29	Amunix Operating Inc	Glucose-regulating polypeptides and methods of making and using same
EP2448593B1 (en)	2009-07-03	2020-11-25	Bionor Immuno AS	Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
BR112012004094A2 (pt)	2009-08-24	2016-03-08	Amunix Operating Inc	composições de fator vii de coagulação e métodos para fazer e usar as mesmas
CA2772104A1 (en)	2009-08-27	2011-03-03	Novartis Ag	Hybrid polypeptides including meningococcal fhbp sequences
US9488656B2 (en)	2009-09-30	2016-11-08	Quest Diagnostics Investments Incorporated	BCR-ABL truncation mutations
WO2011042454A1 (en)	2009-10-06	2011-04-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Carbapenemase and antibacterial treatment
CA2777717C (en)	2009-10-15	2021-05-25	Genentech, Inc.	Chimeric fibroblast growth factors with altered receptor specificity
JP5819308B2 (ja)	2009-10-22	2015-11-24	ジェネンテック，インコーポレイテッド	マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
US20130022633A1 (en)	2009-10-27	2013-01-24	University Of Florence	MENINGOCOCCAL fHBP POLYPEPTIDES
AR078986A1 (es)	2009-11-12	2011-12-14	Genentech Inc	Un metodo para promover la densidad de espinas dendriticas
TWI537383B (zh)	2009-11-30	2016-06-11	建南德克公司	診斷及治療腫瘤之組合物及方法
PE20121799A1 (es)	2009-12-21	2013-01-02	Ambrx Inc	Polipeptidos de somatotropina porcina modificados y sus usos
US20120283171A1 (en)	2009-12-21	2012-11-08	Ambrx, Inc.	Modified bovine somatotropin polypeptides and their uses
FR2954349A1 (fr)	2009-12-22	2011-06-24	Agronomique Inst Nat Rech	Sulfatase modifiant selectivement les glycosaminoglycanes
WO2011106297A2 (en)	2010-02-23	2011-09-01	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
EP4450523A2 (en)	2010-04-02	2024-10-23	Amunix Pharmaceuticals, Inc.	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011139985A1 (en)	2010-05-03	2011-11-10	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
CN103221420A (zh)	2010-05-19	2013-07-24	北卡罗莱纳州立大学	用于递送治疗性肽的组合物和方法
WO2011149461A1 (en)	2010-05-27	2011-12-01	Medtronic, Inc.	Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
KR101768118B1 (ko)	2010-06-25	2017-08-14	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	기도 감염의 치료를 위한 방법 및 약학 조성물
ES2701405T3 (es)	2010-07-29	2019-02-22	Eleven Biotherapeutics Inc	Agonistas y antagonistas del receptor tipo I de IL-1 quimérico
US9567386B2 (en)	2010-08-17	2017-02-14	Ambrx, Inc.	Therapeutic uses of modified relaxin polypeptides
SI3572091T1 (sl)	2010-08-17	2024-07-31	Ambrx, Inc.,	Modificirani polipeptidi relaksina in njihova uporaba
EP2420253A1 (en)	2010-08-20	2012-02-22	Leadartis, S.L.	Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
US8846890B2 (en)	2010-08-30	2014-09-30	Board Of Trustees Of Michigan State University	Microbial nanowires
CN102380091A (zh)	2010-08-31	2012-03-21	健能隆医药技术（上海）有限公司	白介素-22在治疗病毒性肝炎中的应用
EP2616481A4 (en)	2010-09-15	2014-04-02	Aligna Technologies Inc	BIOPRODUCTION OF AROMATIC CHEMICALS FROM LIGNIN DERIVED COMPOUNDS
AR083006A1 (es)	2010-09-23	2013-01-23	Lilly Co Eli	Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
US20150139991A1 (en)	2010-10-15	2015-05-21	Leadartis, S.L.	Generation of multifunctional and multivalent polypeptide complexes with collagen xviii trimerization domain
EP2441776A1 (en)	2010-10-15	2012-04-18	Leadartis, S.L.	Generation of multifunctional and multivalent polypeptide complexes with collagen XVIII trimerization domain
EP2655607A4 (en)	2010-12-21	2014-05-14	Univ North Carolina	METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
US8603740B2 (en)	2010-12-29	2013-12-10	Quest Diagnostics Investments Incorporated	BCR-ABL1 splice variants and uses thereof
WO2012095684A1 (en)	2011-01-10	2012-07-19	Inserm ( Institut National De La Sante Et De La Recherche Medicale)	Methods for the screening of substances useful for the prevention and treatment of neisseria infections
WO2012103240A2 (en)	2011-01-25	2012-08-02	Eleven Biotherapeutics, Inc.	Receptor binding agents
MX343729B (es)	2011-04-08	2016-11-18	Amgen Inc	Factor de diferenciación de crecimiento 15 (gdf-15) y composiciones del mismo para usarse en el tratamiento o mejoramiento de trastornos metabólicos.
WO2013011072A1 (en)	2011-07-20	2013-01-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Carbapenemase and antibacterial treatment
US20140341843A1 (en)	2011-07-29	2014-11-20	Eleven Biotherapeutics, Inc.	Purified proteins
WO2013033456A2 (en)	2011-09-02	2013-03-07	Board Of Trustees Of Michigan State University	Microbial nanowires and methods of making and using
KR20140125803A (ko)	2012-01-26	2014-10-29	암젠 인크	성장 분화 인자 15(gdf-15) 폴리펩타이드들
SG10201606783RA (en)	2012-02-15	2016-10-28	Amunix Operating Inc	Factor viii compositions and methods of making and using same
BR112014019901A8 (pt)	2012-02-15	2018-01-02	Biogen Idec Inc	Proteínas de fator viii recombinante
CN104302408B (zh)	2012-02-27	2016-12-14	阿穆尼克斯运营公司	Xten缀合组合物和制造其的方法
SG10201508420VA (en)	2012-03-27	2015-11-27	Genentech Inc	Improved harvest operations for recombinant proteins
EP2841087B1 (en)	2012-04-27	2017-08-23	The United States of America, as represented by The Secretary, Department of Health and Human Services	Vascular endothelial growth factor antagonists and methods for their use
CN104540850B (zh)	2012-05-03	2018-05-18	西兰制药公司	胰高血糖素样肽2(glp-2)类似物
US10335482B2 (en)	2012-06-06	2019-07-02	Bionor Immuno As	Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer
CA3133302A1 (en)	2012-07-20	2014-01-23	Taiga Biotechnologies, Inc.	Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
WO2014026136A2 (en)	2012-08-10	2014-02-13	Cytomx Therapeutics, Inc.	Protease-resistant systems for polypeptide display and methods of making and using thereof
AU2013348029A1 (en)	2012-11-20	2015-07-02	The University Of North Carolina At Chapel Hill	Methods and compositions for modified factor IX proteins
BR112015012986A2 (pt)	2012-12-07	2017-09-12	Danisco Us Inc	composições e métodos de uso
BR112015012968A2 (pt)	2012-12-07	2017-09-12	Danisco Us Inc	composições e métodos de uso
US10272115B2 (en)	2013-03-11	2019-04-30	Taiga Biotechnologies, Inc.	Production and use of red blood cells
PL2968468T3 (pl)	2013-03-13	2021-12-20	Buzzard Pharmaceuticals AB	Preparaty chimerycznej cytokiny do dostarczania do oka
BR112015023140A8 (pt)	2013-03-15	2018-01-23	Genentech Inc	proteínas de fusão, método para a fabricação da proteína de fusão, composições, ácido nucleico,vetor, célula hospedeira, métodos de produção de uma proteína de fusão, de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana, de tratamento da lesão renal, para acelerar ou melhorar a cicatrização, para a prevenção ou tratamento de uma condição cardiovascular, para tratamento da síndrome metabólica e para tratamento da endotoxemia.
PT3611180T (pt)	2013-03-15	2022-03-15	Biomolecular Holdings Llc	Imunoglobulina híbrida que contém uma ligação não peptídica
WO2015007337A1 (en)	2013-07-19	2015-01-22	Bionor Immuno As	Method for the vaccination against hiv
TWI667255B (zh)	2013-08-14	2019-08-01	美商生物化學醫療公司	因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
US10767156B2 (en)	2013-10-24	2020-09-08	Yeda Research And Development Co., Ltd.	Polynucleotides encoding BREX system polypeptides and methods of using same
JP2016535770A (ja)	2013-11-01	2016-11-17	スフェリウムバイオメッドエス．エル．	治療用及び美容用物質を経皮送達するための封入体
CN104623637A (zh)	2013-11-07	2015-05-20	健能隆医药技术（上海）有限公司	Il-22二聚体在制备静脉注射药物中的应用
WO2015116902A1 (en)	2014-01-31	2015-08-06	Genentech, Inc.	G-protein coupled receptors in hedgehog signaling
EP3116486B1 (en)	2014-03-14	2019-12-04	Daniel J. Capon	Hybrid immunoglobulin containing non-peptidyl linkage
US20170165321A1 (en)	2014-07-11	2017-06-15	Bionor Immuno As	Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
EP3201331A1 (en)	2014-09-30	2017-08-09	Danisco US Inc.	Compositions comprising beta mannanase and methods of use
WO2016054185A1 (en)	2014-09-30	2016-04-07	Danisco Us Inc	Compositions comprising beta-mannanase and methods of use
US20170233707A1 (en)	2014-09-30	2017-08-17	Danisco Us Inc	Compositions comprising beta-mannanase and methods of use
US20170211054A1 (en)	2014-09-30	2017-07-27	Dansico Us Inc.	Compositions comprising beta mannanase and methods of use
WO2016054176A1 (en)	2014-09-30	2016-04-07	Danisco Us Inc	Compositions comprising beta-mannanase and methods of use
BR112017008157A2 (pt)	2014-10-24	2017-12-19	Bristol Myers Squibb Co	polipeptídeos de fgf-21 modificados e usos dos mesmos
WO2016100837A1 (en)	2014-12-18	2016-06-23	Danisco Us Inc	Engineered multifunctional enzymes and methods of use
US20180002683A1 (en)	2014-12-18	2018-01-04	Danisco Us Inc.	Engineered multifunctional enzymes and methods of use
WO2016127057A1 (en)	2015-02-06	2016-08-11	The University Of North Carolina At Chapel Hill	Optimized human clotting factor viii gene expression cassettes and their use
AU2016239683B2 (en)	2015-03-31	2022-02-03	Novimmune Sa	Method for optimizing the assembly and production of hetero-multimeric protein complexes
WO2016177833A1 (en)	2015-05-04	2016-11-10	Bionor Immuno As	Dosage regimen for hiv vaccine
CN108472337B (zh)	2015-08-03	2022-11-25	比奥贝拉蒂治疗公司	因子ix融合蛋白以及其制备和使用方法
KR20180038560A (ko)	2015-08-28	2018-04-16	아뮤닉스 오퍼레이팅 인코포레이티드	키메라 폴리펩티드 조립체와 이의 제조 및 사용 방법
JP2019510517A (ja)	2016-03-29	2019-04-18	ジェルター，インコーポレイテッド	細胞質内体積に対するペリプラズム体積の比率が０．５：１および１０：１の間にあるグラム陰性細菌におけるタンパク質の発現
CN109328069B (zh)	2016-04-15	2023-09-01	亿一生物医药开发(上海)有限公司	Il-22在治疗坏死性小肠结肠炎中的用途
US10590426B2 (en)	2016-08-22	2020-03-17	Board Of Trustees Of Michigan State University	Genetic control of cell size
IL293611A (en)	2016-12-02	2022-08-01	Taiga Biotechnologies Inc	Nanoparticle formulations
AU2017370682A1 (en)	2016-12-06	2019-06-20	Kaleido Biosciences, Inc.	Glycan polymers and related methods thereof
IL250479A0 (en)	2017-02-06	2017-03-30	Sorek Rotem	Genetically engineered cells expressing a disarm system that confers resistance to phages and methods for their production
AU2018219283B2 (en)	2017-02-08	2022-05-19	Bristol-Myers Squibb Company	Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2018152496A1 (en)	2017-02-17	2018-08-23	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Compositions and methods for the diagnosis and treatment of zika virus infection
JP6731114B2 (ja)	2017-08-03	2020-07-29	タイガバイオテクノロジーズ，インク．	メラノーマの処置のための方法および組成物
US10149898B2 (en)	2017-08-03	2018-12-11	Taiga Biotechnologies, Inc.	Methods and compositions for the treatment of melanoma
US11180541B2 (en)	2017-09-28	2021-11-23	Geltor, Inc.	Recombinant collagen and elastin molecules and uses thereof
TWI835772B (zh)	2018-01-26	2024-03-21	美商建南德克公司	Il-22fc融合蛋白及使用方法
KR20200125590A (ko)	2018-01-26	2020-11-04	제넨테크, 인크.	조성물 및 사용 방법
JP2021514354A (ja)	2018-02-21	2021-06-10	ジェネンテック，インコーポレイテッド	ＩＬ−２２Ｆｃ融合タンパク質による治療のための投与
IL258467A (en)	2018-03-29	2018-07-04	Ilana Kolodkin Gal	Methods of disrupting a biofilm and/or preventing formation of same
CN111954537A (zh)	2018-04-09	2020-11-17	美国安进公司	生长分化因子15融合蛋白
SG11202010767SA (en)	2018-05-18	2020-11-27	Bioverativ Therapeutics Inc	Methods of treating hemophilia a
EP3802601A1 (en)	2018-06-06	2021-04-14	Leadartis, S.L.	Trimeric polypeptide complexes and uses thereof
SG11202102427XA (en)	2018-09-11	2021-04-29	Ambrx Inc	Interleukin-2 polypeptide conjugates and their uses
US20220175807A1 (en)	2019-03-31	2022-06-09	Yeda Research And Development Co. Ltd.	Anti-viral and anti-tumoral compounds
JP2022526434A (ja)	2019-04-12	2022-05-24	ジェルター，インコーポレイテッド	組換えエラスチンおよびその産生
KR102134418B1 (ko) *	2019-06-17	2020-07-16	씨제이제일제당 주식회사	L-타이로신을 생산하는 미생물 및 이를 이용한 l-타이로신 생산 방법
KR20220151202A (ko)	2020-03-11	2022-11-14	암브룩스, 인코포레이티드	인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법
WO2021207662A1 (en)	2020-04-10	2021-10-14	Genentech, Inc.	Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
IL288680A (en)	2021-12-05	2023-07-01	Yeda Res & Dev	Genetically modified phages and their use
WO2024133316A1 (en)	2022-12-23	2024-06-27	Thermo Fisher Scientific Baltics Uab	Closed system for expressing recombinant proteins using e. coli and methods for producing clarified cell cultures thereof
WO2024175788A2 (en)	2023-02-23	2024-08-29	Micropep Technologies S.A.	Methods and compositions for production and purification of peptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4237224A (en) *	1974-11-04	1980-12-02	Board Of Trustees Of The Leland Stanford Jr. University	Process for producing biologically functional molecular chimeras
US4366246A (en) *	1977-11-08	1982-12-28	Genentech, Inc.	Method for microbial polypeptide expression
AT373279B (de) *	1977-11-08	1984-01-10	Genentech Inc	Verfahren zur herstellung eines rekombinationsclonbildungstraegers
FI793884A (fi) *	1978-12-26	1980-06-27	Cetus Corp	Stabila plasmider med stort kopieantal
US4631257A (en)	1978-12-26	1986-12-23	Cetus Corporation	Stable high copy number plasmids
US4332892A (en)	1979-01-15	1982-06-01	President And Fellows Of Harvard College	Protein synthesis
AU542264B2 (en) *	1979-06-01	1985-02-14	G.D. Searle & Co.	Plasmid vectors
US4342832A (en) *	1979-07-05	1982-08-03	Genentech, Inc.	Method of constructing a replicable cloning vehicle having quasi-synthetic genes
GB2068970B (en) *	1980-02-06	1983-06-22	Searle & Co	Recombinant dna technique for the preparation of a protein resembling human interferon
DK33181A (da) *	1980-02-06	1981-08-07	Searle & Co	Fremgangsmaade til fremstilling af et interferonlignende protein
CH657141A5 (de) *	1980-07-01	1986-08-15	Hoffmann La Roche	Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
GR81946B (fi) *	1980-09-25	1984-12-12	Genentech Inc
JPS5780398A (en) *	1980-11-05	1982-05-19	Sanraku Inc	Plasmid produced by genetic manipulation, coliform bacillus having the same and preparation of tryptophan with said bacillus
DK489481A (da) *	1980-11-10	1982-05-11	Searle & Co	Plasmidvektor og frmgangsmaade til fremstilling deraf
US5145782A (en) *	1980-12-08	1992-09-08	The Regents Of The University Of California	DNA expression vector suitable for direct expression of a foreign gene
CA1192151A (en) *	1980-12-12	1985-08-20	Cornelis T. Verrips	Dna sequences encoding the various allelic forms of mature thaumatin, and cloning vehicles comprising said dna's and their use in transformed microorganisms

1981
- 1981-03-02 ZA ZA00811368A patent/ZA811368B/xx unknown
- 1981-03-03 BG BG078443A patent/BG46005A3/xx unknown
- 1981-03-13 ZW ZW54/81A patent/ZW5481A1/xx unknown
- 1981-03-20 CA CA000373565A patent/CA1198068A/en not_active Expired
- 1981-03-20 FI FI810876A patent/FI810876L/fi not_active Application Discontinuation
- 1981-03-20 GR GR64454A patent/GR74818B/el unknown
- 1981-03-23 PH PH25398A patent/PH17537A/en unknown
- 1981-03-23 CS CS816230A patent/CS238645B2/cs unknown
- 1981-03-23 BG BG078444A patent/BG45220A3/xx unknown
- 1981-03-23 HU HU81732A patent/HU195534B/hu unknown
- 1981-03-23 DD DD81243408A patent/DD203746A5/de unknown
- 1981-03-23 IE IE657/86A patent/IE51894B1/en not_active IP Right Cessation
- 1981-03-23 EP EP85100548A patent/EP0154133B1/en not_active Expired - Lifetime
- 1981-03-23 NZ NZ196584A patent/NZ196584A/en unknown
- 1981-03-23 FR FR8105732A patent/FR2480781B1/fr not_active Expired
- 1981-03-23 IE IE656/86A patent/IE51893B1/en not_active IP Right Cessation
- 1981-03-23 DK DK198101299A patent/DK173085B1/da active
- 1981-03-23 AT AT83200301T patent/ATE27306T1/de not_active IP Right Cessation
- 1981-03-23 OA OA57360A patent/OA06774A/xx unknown
- 1981-03-23 KR KR1019810000949A patent/KR830005351A/ko unknown
- 1981-03-23 CS CS816231A patent/CS238646B2/cs unknown
- 1981-03-23 IE IE636/81A patent/IE51892B1/en not_active IP Right Cessation
- 1981-03-23 ES ES500617A patent/ES500617A0/es active Granted
- 1981-03-23 DE DE8585100548T patent/DE3177179D1/de not_active Expired - Lifetime
- 1981-03-23 IL IL71885A patent/IL71885A/xx not_active IP Right Cessation
- 1981-03-23 DE DE8181301227T patent/DE3176737D1/de not_active Expired
- 1981-03-23 DE DE19813111405 patent/DE3111405A1/de active Granted
- 1981-03-23 DE DE8383200301T patent/DE3176205D1/de not_active Expired
- 1981-03-23 EP EP83200301A patent/EP0086548B1/en not_active Expired
- 1981-03-23 BR BR8101712A patent/BR8101712A/pt not_active IP Right Cessation
- 1981-03-23 EP EP81301227A patent/EP0036776B1/en not_active Expired
- 1981-03-23 BG BG051341A patent/BG42526A3/xx unknown
- 1981-03-23 AR AR81284705A patent/AR248050A1/es active
- 1981-03-23 NZ NZ207660A patent/NZ207660A/en unknown
- 1981-03-23 NO NO810986A patent/NO810986L/no unknown
- 1981-03-23 JP JP56040529A patent/JPH0724582B2/ja not_active Expired - Lifetime
- 1981-03-23 IL IL62460A patent/IL62460A/xx not_active IP Right Cessation
- 1981-03-23 YU YU756/81A patent/YU45534B/xx unknown
- 1981-03-23 AT AT85100548T patent/ATE52802T1/de not_active IP Right Cessation
- 1981-03-23 DE DE3153606A patent/DE3153606C2/de not_active Expired - Lifetime
- 1981-03-23 GB GB8108986A patent/GB2073203B/en not_active Expired
- 1981-03-23 AT AT81301227T patent/ATE34183T1/de active
- 1981-03-23 IT IT67406/81A patent/IT1144324B/it active
- 1981-03-23 NZ NZ207659A patent/NZ207659A/en unknown
- 1981-03-23 AU AU68636/81A patent/AU542640B2/en not_active Expired
- 1981-03-23 DD DD81228534A patent/DD159435A5/de unknown
- 1981-03-23 PT PT72716A patent/PT72716B/pt unknown
- 1981-03-23 DD DD81243409A patent/DD204494A5/de unknown
- 1981-03-23 CS CS812106A patent/CS238612B2/cs unknown
- 1981-03-24 MX MX81101935U patent/MX7689E/es unknown
- 1981-03-24 PL PL81230296A patent/PL162227B1/pl unknown
- 1981-03-24 PL PL1981252630A patent/PL147727B1/pl unknown
- 1981-03-24 DZ DZ816135A patent/DZ278A1/fr active
1982
- 1982-02-26 ES ES509936A patent/ES8305042A1/es not_active Expired
- 1982-02-26 ES ES509935A patent/ES509935A0/es active Granted
- 1982-11-12 PH PH28133A patent/PH18915A/en unknown
- 1982-11-12 PH PH28135A patent/PH20736A/en unknown
- 1982-11-12 PH PH28134A patent/PH20110A/en unknown
1984
- 1984-02-14 YU YU00260/84A patent/YU26084A/xx unknown
- 1984-05-21 IL IL71885A patent/IL71885A0/xx unknown
- 1984-06-27 AU AU29964/84A patent/AU580959B2/en not_active Expired
- 1984-06-27 AU AU29963/84A patent/AU585832B2/en not_active Expired
- 1984-09-18 NO NO84843719A patent/NO165644C/no not_active IP Right Cessation
- 1984-09-18 NO NO84843718A patent/NO161572C/no not_active IP Right Cessation
- 1984-12-19 FR FR8419450A patent/FR2555199B1/fr not_active Expired
1985
- 1985-05-21 CA CA000482003A patent/CA1213539A/en not_active Expired
- 1985-09-12 FI FI853489A patent/FI72344C/fi not_active IP Right Cessation
- 1985-09-12 FI FI853488A patent/FI853488L/fi not_active Application Discontinuation
- 1985-12-30 MY MY896/85A patent/MY8500896A/xx unknown
1986
- 1986-03-29 KR KR1019860002404A patent/KR860001230B1/ko not_active IP Right Cessation
1992
- 1992-10-13 JP JP4274165A patent/JPH0673469B2/ja not_active Expired - Lifetime
- 1992-10-13 JP JP4274172A patent/JPH0734747B2/ja not_active Expired - Lifetime
1993
- 1993-04-29 US US08/055,960 patent/US5888808A/en not_active Expired - Lifetime
1995
- 1995-06-06 US US08/482,321 patent/US6333174B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0036776B1 (en)	1988-05-11
EP0086548A2 (en)	1983-08-24
EP0036776A2 (en)	1981-09-30
MX7689E (es)	1990-08-14
NZ207660A (en)	1985-12-13
ES509936A0 (es)	1983-04-01
YU45534B (en)	1992-05-28
IL71885A (en)	1986-01-31
KR830005351A (ko)	1983-08-13
EP0086548B1 (en)	1987-05-20
ES8304206A1 (es)	1983-03-16
ES8305042A1 (es)	1983-04-01
ES8207220A1 (es)	1982-09-16
IE51892B1 (en)	1987-04-29
NO161572B (no)	1989-05-22
FR2555199A1 (fr)	1985-05-24
CS238612B2 (en)	1985-12-16
IE51893B1 (en)	1987-04-29
YU75681A (en)	1985-03-20
FR2480781B1 (fr)	1985-10-18
IT1144324B (it)	1986-10-29
NO165644C (no)	1991-03-13
FI853488A0 (fi)	1985-09-12
ATE27306T1 (de)	1987-06-15
FR2555199B1 (fr)	1987-09-04
IL62460A (en)	1986-01-31
EP0154133A3 (en)	1986-05-28
ATE52802T1 (de)	1990-06-15
NZ196584A (en)	1985-12-13
YU26084A (en)	1989-02-28
PL162227B1 (pl)	1993-09-30
PL230296A1 (fi)	1982-01-18
DK129981A (da)	1981-09-25
IE810656L (en)	1981-09-25
HU195534B (en)	1988-05-30
FR2480781A1 (fr)	1981-10-23
NO843719L (no)	1981-09-25
FI853489A0 (fi)	1985-09-12
JPH05211885A (ja)	1993-08-24
IT8167406A0 (it)	1981-03-23
GB2073203B (en)	1984-02-29
BG45220A3 (bg)	1989-04-14
FI853488L (fi)	1985-09-12
PT72716A (en)	1981-04-01
DE3177179D1 (de)	1990-06-21
NO165644B (no)	1990-12-03
US5888808A (en)	1999-03-30
MY8500896A (en)	1985-12-31
IL62460A0 (en)	1981-05-20
JPH0724582B2 (ja)	1995-03-22
PT72716B (en)	1982-03-19
DZ278A1 (fr)	2004-09-13
ATE34183T1 (de)	1988-05-15
EP0154133A2 (en)	1985-09-11
GB2073203A (en)	1981-10-14
FI853489L (fi)	1985-09-12
AU2996484A (en)	1984-10-18
DE3153606C2 (fi)	1991-04-25
NO161572C (no)	1989-08-30
ES509935A0 (es)	1983-03-16
JPH05268962A (ja)	1993-10-19
JPH0734747B2 (ja)	1995-04-19
EP0154133B1 (en)	1990-05-16
PL147727B1 (en)	1989-07-31
DE3176205D1 (en)	1987-06-25
PH20736A (en)	1987-04-02
GR74818B (fi)	1984-07-12
CA1198068A (en)	1985-12-17
AU2996384A (en)	1984-10-18
ES500617A0 (es)	1982-09-16
IL71885A0 (en)	1984-09-30
NO810986L (no)	1981-09-25
FI72344B (fi)	1987-01-30
EP0036776A3 (en)	1982-10-27
BG46005A3 (en)	1989-09-15
PH18915A (en)	1985-11-06
DD203746A5 (de)	1983-11-02
FI72344C (fi)	1987-05-11
IE51894B1 (en)	1987-04-29
BG42526A3 (en)	1987-12-15
FI810876L (fi)	1981-09-25
KR860001230B1 (ko)	1986-08-30
JPH0673469B2 (ja)	1994-09-21
AR248050A1 (es)	1995-05-31
OA06774A (fr)	1982-06-30
AU542640B2 (en)	1985-02-28
NZ207659A (en)	1985-12-13
AU580959B2 (en)	1989-02-09
CS238646B2 (en)	1985-12-16
DE3111405A1 (de)	1982-03-25
DD159435A5 (de)	1983-03-09
NO843718L (no)	1981-09-25
DD204494A5 (de)	1983-11-30
PH17537A (en)	1984-09-19
JPS56145221A (en)	1981-11-11
ZA811368B (en)	1982-04-28
DE3111405C2 (fi)	1990-06-21
IE860657L (en)	1981-09-24
ZW5481A1 (en)	1981-10-21
CS238645B2 (en)	1985-12-16
IE810636L (en)	1981-09-24
BR8101712A (pt)	1981-09-29
DE3176737D1 (en)	1988-06-16
EP0086548A3 (en)	1983-11-30
CA1213539A (en)	1986-11-04
AU585832B2 (en)	1989-06-29
AU6863681A (en)	1981-10-01
PH20110A (en)	1986-09-29
US6333174B1 (en)	2001-12-25

Publication	Publication Date	Title
DK173085B1 (da)	1999-12-27	Fremgangsmåde til bakteriel polypeptidudtrykkelse og plasmidisk udtrykkelsesmedium til fremstilling af et heterologt polype
EP0075444B1 (en)	1992-12-23	Methods and products for facile microbial expression of dna sequences
DK170477B1 (da)	1995-09-11	Mikrobiel hybrid promotor/operator, vektor og udtrykkelsesvektor indeholdende denne, og E. coli stamme transformeret med udtrykkelsesvektoren, kultur af E. coli stammen og fremgangsmåde til mikrobiel produktion af heterologe polypeptider under anvendelse af kulturen
US4663283A (en)	1987-05-05	Method of altering double-stranded DNA
EP0104061A1 (en)	1984-03-28	Improved expression vectors
EP0040466B1 (en)	1987-11-11	Adaptor molecules for dna and their application to synthesis of gene-derived products
EP0179786B1 (en)	1990-05-16	High copy number expression vectors
GB2104901A (en)	1983-03-16	Expression vectors
CA2057715A1 (en)	1992-06-20	Method for enhancing the structural stability of recombinant dna expression vectors
DK173822B1 (da)	2001-11-19	Fremgangsmåde til fremstilling af bovint væksthormon
EP0197558A2 (en)	1986-10-15	Process for production of somatostatin